Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma

Although molecular heterogenicity of diffuse large B-cell lymphoma (DLBCL) with regards to cell-of-origin (COO) was first described nearly 20 years ago, limitations of technology used to assess COO precluded prospective, real time implementation in clinical trials until recently. Advances in COO